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Malignancies associated with Epstein–Barr virus (EBV) and/or Kaposi’s sarcoma human
herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is frequently found in
patients infected with HIV. Both these human gammaherpesviruses are known for their
oncogenic properties, for the viral products that mimic or interfere with the functions of
critical cellular proteins, and the ability to escape the immune responses. The introduction
of the highly active anti-retroviral therapy (HAART) has signiﬁcantly decreased the fre-
quency of Kaposi’s sarcoma (KS), non-Hodgkin’s lymphoma (NHL), and primary central
nervous system lymphoma (PCNSL); conversely, for some lymphomas the incidence dimin-
ished only slightly, as in Burkitt’s lymphoma (BL), or had no signiﬁcant variations, as Hodg-
kin’s lymphoma (HL). These observations may indicate that HAART might have a direct
impact on KSHV and EBV biology, that there is a reconstitution of the immune system in
HIV-infected patients under HAART, or even that HAART perhaps has a detrimental impact
in the pathogenic interactions between HIV, EBV and KSHV. The present review aim to
evaluate and to discuss the data available for these hypotheses, in order to shed more light
on the mechanisms for the cooperation among HIV-1, EBV and KSHV that may culminate in
cell transformation and cancer development in humans.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Malignancies in individuals infected by the Human
Immunodeﬁciency Virus (HIV) are frequently associated
with co-infection by the Epstein–Barr virus (EBV), and/or
the Kaposi’s sarcoma-associated herpesvirus (KSHV) [1].
EBV and KSHV, also known as human herpesvirus 4
(HHV-4) and Human Herpesvirus-8 (HHV-8), respectively,
are two gammaherpesviruses with known oncogenic prop-
erties for humans [2]. In the HIV infection setting, EBV is
found in neoplastic cells in most of the Hodgkin’s
lymphoma (HL) cases, as well as in some non-Hodgkin’s
lymphomas (NHL), including Burkitt’s lymphoma (BL),edicina de Botucatu,
n – Botucatu, SP, CEP
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nder the Elsevier OA license.Diffuse Large B-cell lymphoma (DLBCL) of immunoblas-
tic-plasmacytoid type, plasmablastic lymphomas, primary
central nervous system lymphoma (PCNSL) and primary
effusion lymphoma (PEL) [3]. In the other hand, KSHV is
conclusively associated with all cases of Kaposi’s sarcoma
(KS) [4], and PEL [5].
Individuals infected by HIV have a 60–200-fold and
8–10-fold higher relative risk to develop NHL and HL,
respectively, compared to the HIV-negative population.
The degree of impairment of the immune system was sug-
gested to be related with the development of speciﬁc NHL
in HIV-positive patients. For instance, individuals with
normal or slightly decreased number of circulating T CDþ4
lymphocytes have a higher risk of BL and centroblastic
DLBCL, whist the risk of PEL and plasmablastic DLBCL is
higher among patients with severe immunodeﬁciency [6].
The incidence of KS in individuals infected with HIV, on
the other hand, is 20,000-fold higher than in general
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other type of immunosuppression [7]. It has been previ-
ously reported that individuals co-infected with KSHV
and HIV-1 have an increase of 60% in the probability for
developing KS, per year of post HIV-infection [8].
With the introduction of the highly active anti-
retroviral therapy (HAART), around 1990, there were
changes in the frequency of cancers associated with the
Acquired Immunodeﬁciency Syndrome (AIDS). Notably, it
was noted a signiﬁcantly decrease in KS and a small de-
crease in NHL cases; the frequency of PCNSL, though, had
declined drastically [9–14].
As KS is consistently linked with KSHV, and some of the
NHL are linked with EBV and/or KSHV, few hypotheses
may be considered to explain the decrease in the incidence
of these cancers in the post-HAART era (Fig. 1). First,
HAART might have some direct impact on KSHV and EBV
reactivation and replication, with reﬂections in their viral
load. Second, because of the partial reconstitution of the
immune system, HAART-treated HIV-positive patients
might have a better control over primary infection (mostly
for KSHV), as well as viral reactivation (for both KSHV and
EBV). This would decrease the odds for long-term cell
transformation by the oncogenic gammaherpesviruses,
and improve the immunovigilance against virus-trans-
formed cells. And third, as HAART decreases the HIV bur-
den within the organism, it could result in a decreased
interaction between HIV and KSHV and/or EBV, so that vir-
al products that may cooperate for cell transformation will
not. In the post-HAART era, the incidence of BL in HIV-trea-
ted patients was invariable or had increased slightly over-
time [15,16], and there were no signiﬁcant variations in
the frequency of HL [15]. This data suggest lack of a direct
negative impact of HAART in the EBV biology [17].
Although the drastic decrease in the incidence of Aids-
associated KS might indicate that this could be the case
for KSHV, it is also controverse whether some drugs in-
cluded in the anti-retroviral therapy directly affect this
gammaherpesvirus [18]. On the other hand, there is en-
ough data indicating that HAART has a more unspeciﬁc ef-
fect stimulating the immune system [19–25], as presumed
in the second hypothesis. Indeed, the importance of theFig. 1. Hypotheses to be considered to explain the impact of HAART in the develo
on KSHV and EBV reactivation and replication; (2) partial reconstitution of the i
HAART decreases the interaction between HIV and KSHV and/or EBV.immune system status in the pathogenesis of proliferative
diseases and cancers associated with infection by EBV or
KSHV may be even inferred outside the HIV setting. For in-
stance, it is well established the association of EBV with the
development of post-transplant lymphproliferative disease
(PTLD) [26,27], and non-Aids-associated KS lesions also
arises under some degree of immunosuppression (e.g.,
immunosenescence in classic KS) [28].
Conversely, this does not exclude that HAART may also
have an indirect effect impairing the HIV and KSHV and/or
EBV interaction in cancer pathogenesis. Noteworthy, viral
cooperation would explain the higher aggressiveness of
KS in HIV-infected people. The main scope of the present
review is to explore possible mechanisms for viral cooper-
ation in the context of human carcinogenesis; thus, ele-
ments for the third hypothesis previously mentioned will
be discussed further. As diseases implicating HIV, EBV
and KSHV will be used as models, interactions between
those viruses will be considered in order to contribute for
a better understanding on the etiopathogenesis of gamma-
herpesvirus-associated cancers in the HIV setting.
In the following sections, some background information
about the biology of HIV-1, KSHV and EBV will be provided
for better understanding of the known or putative interac-
tions among these viruses for cell transformation and can-
cer development in humans.2. HIV
The HIV genome includes the basic set of retroviral
genes gag, pol and env. Whereas gag encodes structural
(e.g., p24, p7 e p6) and matrix proteins (e.g., p17), pol en-
codes proteins required for HIV replication (the reverse
transcriptase, integrase and protease enzymes), and env
encodes the glycoproteins (e.g., gp120 and gp41) that
interact with the molecules expressed on the surface of
the target cells. Regulatory proteins are also encoded
in the HIV genome, including the regulator of expression
of the virion – rev, the transactivator of transcription –
tat, and four accessories proteins: the negative factor –
nef, the viral protein R – vpr, the viral protein U – vpu,pment of EBV and KSHV-associated cancers. (1) HAART has a direct impact
mmune responses against viral infection as a consequence of HAART; (3)
Table 1
List of major KSHV and EBV homologs for cellular proteins with activity in cell proliferation,
apoptosis and modulation of the immune responses.
Phenomenon KSHV homolog EBV homolog
Cell proliferation vCyc (ORF72)
Apoptosis vbcl-2 (ORF16) BHRF-1 (BamHI fragment
H rightward open reading frame-1)vFLIP (ORF71/
ORFK13)
vIAP (ORFK7)
Immune responses vIL-6 (ORFK2) vIL10 (BCRF1)
vIRF (ORFK9)
vMIPI (ORFK6)
vMIPII (ORFK4)
vGPCR (ORF74)
ORFK14
vCyc – viral cyclin; vFLIP – viral FAS-associated death domain-like interleukin-1b converting
enzyme (FLICE)-like inhibitory protein; vIAP – viral inhibitor-of-apoptosis protein;
vIRF – interferon regulatory factor; vMIP – viral macrophage inhibitory protein; vGPCR –
viral G-protein coupled receptor; neural cells adhesion molecule family transmembrane
protein – N-CAM) [35].
S. Ramos da Silva, D. Elgui de Oliveira / Cancer Letters 305 (2011) 175–185 177and the virus infectivity factor – vif [29]. The main targets
for HIV infection are the CD4-expressing subset of T lym-
phocytes and cells of monocytic/macrophagic lineage.
The CD4 molecule expressed in the cell surface is used by
HIV as a primary receptor. However, successful cell entry
relies also in the interaction between membrane-bound
retroviral gp120 and the cellular CXCR4 or CCR5 molecules
(a and b chemokines receptors), required as co-factors for
gp41-mediated fusion of viral and target cell membranes.
With the introduction of the HIV-1 nucleocapsid in the
cytoplasm, the retroviral RNA released is converted to a
proviral DNA by the reverse transcriptase enzyme. The
proviral DNA is transported to the nucleus and incorpo-
rated to the cellular genome by the retroviral integrase.
The transcription initiation for the integrated provirus re-
lies on the U3-R-U5 sequence in the HIV-1 long terminal
repeat (LTR) via cellular RNA polymerase II. Though the
U3-R-U5 is presented at both ends of the viral DNA, only
the 50 LTR is used for proviral transcription. The retroviral
genomic RNA produced are categorized into three classes:
unspliced RNA, which is exported to the cytoplasm to serve
as mRNA for Gag and Gag-Pol synthesis, and to be included
into the newly-produced viruses; partially splice mRNA,
which encode env, vif, vpu and vpr proteins; and
multiple-spliced RNAs, which encodes rev, tat and nef pro-
teins. Soon after or throughout the virus release from the
plasma membrane, the viral protease cleaves gag and
gag-pol polyproteins, in order to generate gag and pol
mature proteins that characterizes the infectious HIV-1
particles [30].3. Human gammaherpesvirus
The human gammaherpesviruses (Order Hespevirales,
family Hespeviridae, subfamily Gammaherpesvirinae) are
currently subdivided intoﬁve genera, including the Lympho-
cryptovirus and Rhadinovirus, which EBV and KSHV belongs
to, respectively [31]. The EBV and KSHV genomes are
double-strand linear DNAs with approximately 170kpb,
usually kept in the nucleus of the infected cells as circular
episomes. The tropism for lymphocytes is one of the distinct
features of gammaherpesviruses. Once infected, these cells
are driven to sustainedproliferation, and eventually immor-
talization and malignant transformation. Gammaherpesvi-
ruses also have the ability to establish a latent biologic
cycle in infected cells, in which only a limited set of viral
genes are expressed. As episomes, the viral genomes behave
as a cellular chromosome, being replicated and segregated
between daughter cells during the mitosis [32].
Lytic reactivation for all gammaherpesvirus is dependent
on ‘‘switch proteins’’. In KSHV, the Replication and Tran-
scription Activator protein (Rta; viral ORF50) is the main
regulator for expression of lytic genes and viral replication.
EBV, on the other hand, has two different proteins relevant
for the same activities: its own Rta (viral BRLF1) and the
EBV Zta (encoded by BZLF1) [33]. Regulation of lytic reacti-
vation for EBV and KSHV relies also in cellular proteins,
notably the NF-jB family of transcription factors [2,34].
During infection, EBV and KSHV actively hijack the in-
fected host cell via expression of different viral products.Interestingly, some of these products have high degree of
functional and/or structural homology with critical cellular
proteins, which interferes in cell proliferation, apoptosis
and modulates the immune responses. In this regard, rep-
resentative examples are indicated in Table 1. Especially
for KSHV, several of these viral homologs were implicated
in viral-induced cell transformation [2,35].
3.1. Epstein Barr virus – EBV
The primary infection by EBV takes place at the oro-
pharingeal mucosa, where the virus infects intra-epithelial
B lymphocytes (memory and naïve cells), or lymphocytes
adjacent to the epithelial stratum of the mucosa (mainly
naïve cells). The infected naïve B cells are then activated,
even in the absence of external antigenic stimulus. As a re-
sult, the B cell differentiation is blocked and proliferation is
stimulated. Some EBV-infected cells are eliminated by
cytotoxic T lymphocytes, while others evade the immune
response.
EBV-infected-B lymphocytes migrate to germinal center
and differentiate to memory cells. During the migration
the peripheral blood, the expression of EBV proteins in
the infected cells is suspended, so that they mimic non-
infected-B lymphocytes. Throughout the division of the
infected-cell, DNA replication is carried out by the expres-
sion of EBNA-1 EBV protein, which is not properly recog-
nized by the immune system. The viral lytic reactivation
occurs when infected-B lymphocytes receive stimulus to
differentiate into plasma cells, and the signaling cascade
initiated by the B-cell receptor (BCR) results in the expres-
sion of the EBV immediately early (IE) genes BZLF1 and
BRLF1. Their products activate early genes, and the late ly-
tic genes subsequently. Infected plasma-cells migrate to
the oropharingeal mucosa to release infectious EBV parti-
cles, which might infect other B lymphocytes or spread
via saliva [36].
Based on the expression of different set of viral genes
during the latent cycle of EBV, three main distinct latency
programs have been described, namely latency I, II and III.
Just after the viral entry, nine latent viral proteins are ex-
pressed: three Latent Membrane Proteins (LMP-1, LMP-
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EBNA-3a/EBNA-3, EBNA-3b/EBNA-4, EBNA-3c/EBNA-6
and EBNA-LP (leader protein/EBNA-5), as well as two EBV-
encoded small non-polyadenylated RNAs (EBERs/EBER-1
and EBER-2). This expression proﬁle characterizes the la-
tency type III, also known as growth program, as it results
in stimulus for proliferation for newly-infected cells. Fol-
lowing migration of the infected-cells to the lymphoid ger-
minal centers, only EBV EBERs, EBNA-1, LMP-1 and LMP-2A
are expressed, which characterizes the latency type II. In
the germinal center, EBV-infected naïve B lymphocytes dif-
ferentiated into B memory cells, which migrate to the
blood. In this stage there are the expressions of EBNA-1
and EBERs only, the latency type I, also known as the de-
fault program [37]. In EBV-associated malignancies, most
of the neoplastic infected cells show one of these EBV la-
tency programs, as indicated in Table 2.
3.2. Kaposi’s sarcoma herpesvirus – KSHV
KSHV is the most recently-discovered human gamma-
herpesvirus, described in 1994 [38]. Besides being the cau-
sal agent of all forms of KS and PEL [4,5], in HIV-infected
patients it is also associated with the development of the
Multicentric Castleman Disease (MCD), a rare non-
neoplastic lymphoproliferative disorder [39].
The main latent KSHV proteins are the latency-
associated nuclear antigen (LANA), encoded by ORF73,
the viral homolog for the cellular FAS-associated death do-
main-like interleukin-1b converting enzyme (FLICE)-like
inhibitory protein (vFLIP), encoded by ORF71, and the viral
homolog for a cellular D cyclin (vCyc), encoded by ORF72.
These three genes are transcribed from the same promoter
as latent transcript 1 (5.4 kb), which encodes LANA, vCyc
and vFLIP, and latent transcript 2 (1.7 kb), which encodes
vCyc and vFLIP [40–42].
The main function of LANA is the maintenance of the
KSHV epissome (which resembles the function of EBV
EBNA-1), which favors viral persistence [43,44]. LANATable 2
EBV latency programs in neoplastic and non-neoplastic settings (based in
Thorley-Lawson and Gross [36]).
Latency Differently
expressed
EBV
products*
Infected
normal
B cells
EBV-associated
malignancies and
lymphoproliferative
conditions
Type I
(EBNA-1-only)
EBNA-1 Dividing
memory cells
BL
Type II
(default program)
EBNA-1,
LMP-1 and
LMP-2a
Germinal
center cells
cHL, NHL, NC
Type III
(growth program)
EBNA-1, 2,
3a, 3b, 3c,
LP, LMP-1,
LMP-2a
and LMP-
2b
Naïve cells IL, PTLD
* EBERs and BARFs are expressed in all EBV latency programs. BL: Burkitt
lymphomas; cHL, classic Hodgkin lymphomas, NHL: non-Hodgkin lym-
phoma, NC: nasopharyngeal carcinoma, IL: immunoblastic lymphoma;
PTLD: post-transplant lymphoproliferative disorder.interacts with the tumor suppressor protein p53 and inhib-
its its transcriptional activity. As a consequence, genes
associated with DNA repair and apoptosis are downregu-
lated [45]. LANA, therefore, favors the survival of KSHV-
infected cell, contributing for viral dissemination. LANA
can also interfere with the Wnt signaling pathway, as it
interacts with glycogen synthase kinase 3-b (GSK3-b) and
alters its intracellular distribution, promoting nuclear accu-
mulation of b-catenin, which induces expression of genes
as different genes, including MYC, JUN and CCDN1 [46,47].
LANA is also able to transactivate the promoter of the hu-
man telomerase reverse transcriptase (hTERT), via Sp1
interaction [48,49], favoring cell immortalization. Further-
more, it inhibits its own synthesis, degradation and pro-
cessing for antigen presentation, which contributes for
immune evasion of the KSHV-infected cells [50,51]. These
activities make LANA one of the major KSHV oncoproteins.
The ﬁrst activity attributed to KSHV vFLIP was the neg-
ative regulation of apoptosis deﬂagrated by the tumor
necrosis factor receptor (TNFr), as well as inhibition of
caspases [52]. However, the main effects of vFLIP expres-
sion actually relies on constitutive NF-jB activation,
through its interaction with the cellular IjB-kinase [53].
Activation of NF-jB by vFLIP promotes the transcription
of NF-jB-dependent anti-apoptotic cellular genes (as the
endogenous FLIP and inhibitory apoptosis proteins IAP-1
and IAP-2) [54], and blocks the apoptosis induced by the
absence of growth factors [55].
As the endogenous cyclins, vCyc acts in the cell cycle.
However, vCyc has preferential interaction with Cdk-6,
and the vCyc-Cdk-6 complex is less susceptible to the
CDK complex inhibitors p16Ink4A and p27Cip/Kip. The vCyc
expression stimulates the cell cycle G1 to S progression,
inducing DNA synthesis and deregulating the mitosis
[56]. Those activities support the proliferation of KSHV-
infected cells and the viral propagation as well.
Even in theHAARTera, KS still is oneof themost common
AIDS-relatedmalignancies [57], and themost reported can-
cer in Equatorial Africa [58]. It is well established that KSHV
is necessary, but not sufﬁcient for development of KS [59]. In
general, PEL is even less frequent than KS; likewise, how-
ever, it is observed more often in immunocompromised
individuals, namely under HIV-1 infection [3,60]. Thus, it is
plausible to assume that HIV-1 has an important role in
the pathogenesis of KSHV-associated cancers.4. Viral cooperation implicating HIV, EBV and KSHV
It is noteworthy that EBV-associated lymphomas arise
more frequently in the HIV-infected population; as previ-
ously mentioned the same is true for KSHV malignancies.
Thus, it is plausible to assume that HIV infection and
immunosuppression play an important role in the patho-
genesis of both EBV and KSHV-associated cancers. Indeed,
immunosuppression is a fertile soil for emergence of
virally-transformed cells, as they are not properly recog-
nized and eliminated by the host’s immune system.
The HIV-driven impairment of the immune system
likely contributes for the escape of herpesvirus-infected
cells from immune control, allowing their proliferation,
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clones [61,62]. For instance, a striking decline in telomere
length in EBV-speciﬁc CDþ8 T cells was observed in HIV-
positive individuals, compared to HIV-negative subjects.
This could lead to an uncontrolled chronic EBV-infection
due to a decreased proliferative potential of EBV-speciﬁc
T CDþ8 lymphocytes [63], which favors the subversion of
the immune surveillance. On the other hand, it is worth
to note that KS lesions usually arises in HIV-infected indi-
viduals with low T CDþ4 cells counts [64]. As will be dis-
cussed in detail, an increasing body of evidence indicates
that the higher incidence of KS in HIV-positive patients,
as well as the more aggressive course of AIDS-KS compared
to the other forms of the disease, may be related to puta-
tive mechanisms of viral cooperation between HIV and
KSHV.
One important issue to be considered whenever evalu-
ating plausible mechanisms for viral cooperation in carci-
nogenesis is the viral cell tropism, since the infected cells
are supposed to be the main targets for malignant
transformation.
B lymphocytes that express the CR2 (CD21) surface
receptor for the C3d complement fragment are the main
target cells for EBV infection [65]. EBV DNA has also been
detected in the broad CDþ19 B lymphocytes group, as well
as CDþ4 and CD
þ
8 T lymphocytes in children and adolescents
infected with HIV-1 [66]. Interestingly, it was reported that
for CR2+ EBV-transformed B lymphocytes, which usually
co-express CD4, the complex CR2-CD4 increases the cell
susceptibility to HIV-1 entry [67].
Though KSHV has a broad spectrum of cellular tro-
pism, KSHV and HIV also have different target cells for
infection. KSHV infects mainly B lymphocytes, keratino-
cytes, epithelial and endothelial cells [68], whilst HIV in-
fects mainly T CDþ4 lymphocytes. On the other hand, both
may infect dendritic and mononuclear cells [69,70]. It
should be noted that the co-localization of KSHV and
HIV does not seem to be critical for interaction between
these viruses. For instance, in a study published by Aoki
and colleagues in 2004, the authors reported that the
KSHV infectivity of 293 cells was enhanced when they
were incubated with a HIV-1 tat-BR peptide. As the
tat-BR peptides were used in concentrations higher than
that usually found for the retroviral tat in the serum of
HIV-1 patients, it was suggested that lymphoid tissues,
where intense HIV replication take place, could be a
privileged scenario for KSHV infection of its target cells
[71].
Although KSHV and HIV reservoirs of co-infected cells
remains to be conﬁrmed in vivo, HIV-1 replication in PEL
BC-3 cells (KSHV-positive, EBV-negative) in vitro was de-
scribed, and it resulted in KSHV reactivation [72]. On the
other side, an increase in HIV replication was observed in
HIV-1-infected T CDþ4 cells co-cultivated with KSHV-
infected B cells [73]. Interestingly, the same was observed
for HIV-infected monocytes co-cultivated with KSHV-
infected endothelial cells [74]. Based on these results, it
can be assumed that not only the HIV-1 infection have an
important effect for KSHV spread within the host
organism, KSHV also contribute for the HIV-1 burden,
enhancing AIDS progression.Possible mechanisms for EBV, KSHV and HIV-1 interac-
tion have the activation of HIV-1 LTR as a converging point,
which can be deﬂagrated by different herpesviral proteins.
For instance, the EBV EBNA-2 protein activates the HIV-1
LTR in B cells and HeLa epithelial cells, possibly mediated
by the NF-jB signaling [75]. In cell lines transfected with
an EBV EBNA-2 expression vector, the protein is also able
to enhance the transactivation of HIV-1 LTR via tat. Note-
worthy, transactivation of HIV LTR by tat is increased when
CDþ4 cells are infected with EBV type 1, indicating that EBV
improves HIV-1 replication in T lymphocytes [76]. It was
reported that HIV-1 tat protein has also important effects
in EBV-immortalized B lymphocytes, as it is able to change
the cell susceptibility to apoptosis and favors cell cycle
progression, increasing their proliferative capacity [77].
Other EBV products, as the viral DNA polymerase [78]
and LMP-1 [79], also transactivate the HIV-1 LTR, as well
as the immediate-early (IE) gene product BamHI MLF1
[80]. The later, however, does not share the tat-responsive
elements in the HIV-1 promoter [81]. Further EBV IE gene
products capable of inducing the HIV-1 LTR are the BRLF-1,
which is either dependent or independent of the HIV-1 en-
hancer elements [82], and BZLF1, which cooperates with
tat in Hela cells [83].
Conversely, KSHV LANA protein activates the HIV-1 LTR
in BJAB cells at levels similar or higher than the HIV tat
protein. Noteworthy, LANA physically interacts with HIV-
1 tat protein through its carboxy-terminal region, and it
also synergizes with tat to increase the transcriptional
activity of HIV-1 in BJAB, U937 human monocytic cells,
and HEK-293T human embryonic kidney cells [84]. Inter-
esting, in Cos7 cells KSHV LANA inhibited the HIV-1 LTR,
probably as a result of a negative effect on the NF-kB-
dependent transcription. Alternatively, in BJAB cells LANA
induced Staf-50 transcription factor, which is an inhibitor
of the HIV-1 LTR activity [85]. In addition, the early KSHV
KIE-2 protein (viral ORF45) activates HIV-1 LTR when co-
expressed with the retroviral tat protein. Interestingly,
both HIV-1 tat and vpr proteins activate KSHV KIE2 [86],
which may create another ampliﬁcation loop for LTR
activation.
Both EBV and KSHV disturb the NF-jB pathway in the
infected cells [87], and this may have a critical effect in
the HIV-1 biology. In 293T and Cos7 cells, the HIV-1 LTR
may be activated by KSHV vFLIP via the NF-jB-classical
pathway, and this interaction is inﬂuenced by the number
of NF-jB binding sites in the retroviral LTR, which differs
according to HIV-1 genotypic strain. Moreover, vFLIP coop-
erates with HIV-1 tat to synergically activate the retroviral
LTR, which result in an ampliﬁcation loop that enhances tat
activity. This could result in an increase in HIV replication,
mainly in early stages of HIV-infection or in cells with
downregulated tat [88].
As it is becoming evident, the HIV tat protein plays a
critical role in many of the putative mechanisms of viral
cooperation with EBV or KSHV in human carcinogenesis.
Remarkably, the phenotype of the fusiform neoplastic cells
in KS is partially attributed to HIV-1 tat activity: this retro-
viral protein can induce KS-like lesions in nude mice via
secretion of interferon-c (IFN-c), which has pro-angiogenic
properties and it is produced by inﬂammatory cells present
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macrophages [89]. The HIV-1 tat induces angiogenesis
through the activation of the Vascular Endothelial Growth
Factor Receptor 2 (VEGFR-2) in endothelial cells [90];
furthermore, it stimulates the development of KS-like le-
sions [91,92]. Interestingly, the two-exon-encoded HIV-1
tat – but not the one-exon-encoded version of the protein
– promotes growth of the KS cell line SLK in transgenic
mice [93].
A relevant link between HIV-1 tat and KS pathogenesis
involves the activity of cell surface adhesion molecules.
AIDS-KS and normal vascular cells exposed to inﬂamma-
tory cytokines have increased adhesion due to the expres-
sion of the HIV-1 tat. This adhesion is attributable to tat
amino acid sequence RGD, which interacts with integrin
receptors a5b1 and avb3. Integrins mediate the growth-
promoting effect of HIV-1 tat protein on vascular cells
[94]. Moreover, HIV-1 tat mimics matrix proteins, promot-
ing adhesion, migration, and cellular invasion, and also
mobilizes the basic ﬁbroblast growth factor (bFGF), which
has important angiogenic properties and may enhance KS
progression in HIV-infected patients [95].
Another possible mechanism to be considered for viral
cooperation involving HIV-1, EBV and KSHV, is dependent
on the crosstalk among the biological cycles of these
viruses. In this setting, much more is known about the
interactions between HIV-1 and KSHV, compared to HIV-
1 and EBV.
A decrease in the number of T CDþ4 lymphocytes early in
HIV infection was reported to have an important impact in
the control of EBV latency and viral reactivation [96]. Over-
all, EBV reactivation is inversely related to the T CDþ8 activ-
ity against EBV, so that a progressive impairment in
intensity and extensiveness of EBV-directed immune re-
sponse is observed throughout the natural history of
HIV-1 infection [97]. Interestingly, it was previously re-
ported that the retroviral infection activates EBV, as well
as upregulates the expression of the c-myc transcription
factor in primary human B cells infected with HIV-1,
resulting in increased proliferation of EBV-immortalized
cells [98]. These observations indicate that the crosstalk
between HIV-1 and EBV life cycles not only is relevant, it
also urges further investigation, as the available informa-
tion on this matter in the literature is currently sparse.
On the other side, the mechanisms for the crosstalk be-
tween the HIV-1 and KSHV life cycles may be approached
considering the main players in viral activation: the HIV
LTR and KSHV Rta protein. In BCBL-1 and HL3T1 cells, the
interaction between the KSHV Rta (ORF50) and HIV-1 tat
protein synergistically transactivates the HIV-1 LTR, prob-
ably by a post-transcriptional mechanism. Though KSHV
ORF57 also increases the transactivation of the HIV-1
LTR, it does not interact directly with tat, and this effect
is possibly due to induction of KSHV Rta. Interesting, trans-
activation of HIV-1 LTR is partly inhibited when both KSHV
Rta and the ORF57 protein were expressed [99]. Addition-
ally, in cell lines permissive to HIV infection (as Jurkat and
BC-3), KSHV Rta increases the HIV-1 replication, whilst in
HIV non-permissive cells (as A172 glial cells) the
expression of KSHV Rta causes vulnerability and transitory
permissiveness to HIV infection [100].It was reported that the HIV-1 activates the KSHV Rt
apromoter, causing KSHV lytic replication; this effect rel-
lies on proteins other than the retroviral tat [101]. Rather
than direct activating KSHV ORF50, HIV-1 tat induce KSHV
lytic cycle in BCBL-1 cells through IL-6 expression and acti-
vation of the JAK2/STAT3 signaling pathway. In this model,
tat stimulates the GATA3 protein, which induces IL-4
expression and activation of STAT6, which in turn inﬂu-
ences tat-induced KSHV replication [102]. KSHV replica-
tion can also be induced by other cytokines, as oncostatin
M (OSM) and the hepatocyte growth factor/scatter factor
(HGF/SF), which are produced by, or in response to HIV-
infected cells [73].
The anti-retroviral therapy (ART) can prevent the KSHV
lytic reactivation in HIV-infected BC-3 cells, and it reduces
the transmission of KSHV virions to non-infected cells
[103]. Actually, the decrease in KS incidence promoted by
ART may indeed be explained in part by the fact that
HIV-1 tat increases the KSHV infectivity. As ART decreases
HIV-1 burden in the host, there is also a decrease in the
production of the retroviral tat, which may explain the det-
rimental effect of ART in KSHV biology. It should be noted,
however, that the levels of HIV-1 tat protein required to in-
crease KSHV infectivity were reported to be 10–15-fold
higher than the levels detected in the serum of HIV-
infected people [71]. Therefore, the paracrine activity of
retroviral tat in KSHV-infected cells may be biologically
relevant mainly in sites of more intense HIV-1 replication.
Considering the available body of data, there is substan-
tial evidence that HIV-1 tat really plays a pivotal role
enhancing the KSHV oncogenicity in individuals infected
by both viruses. HIV-1 tat may even contribute in the KS
pathogenesis targeting multiple cellular pathways through
KSHV proteins. For instance, it was reported that the retro-
viral tat increase the KSHV vGPCR signaling, which re-
sulted in accelerated tumorigenesis in vivo; of note, there
is no requirement of co-expression of HIV-1 tat and KSHV
vGPCR in the same cells for this effect [104]. In HUT 78-
lymphoid cells, primary endothelial cells, and a KSHV-neg-
ative KS-derived endothelial cell line, the HIV-1 tat protein
also cooperates with KSHV vGPCR to active the nuclear fac-
tors of activated T cells (NF-AT), NF-AT1 and NF-AT-2, and
the NF-jB pathway [105]. Importantly, KSHV vGPCR tran-
scripts are detected in AIDS-KS, but not in classic KS sam-
ples [106]. Tat also promotes proliferation of the NIH3T3
cells and accelerates tumorigenesis caused by KSHV kapo-
sin A in nude mice, through enhancement of kaposin
A-induced signaling involving MEK/ERK, STAT3 and PI3K/
Akt [107].
Curiously, KSHV proteins homologs to cellular macro-
phage inﬂammatory protein (MIP) may interfere in co-
receptors used by HIV-1 for infection of its target cells.
The KSHV vMIP-I (ORFK6) attach to CCR5, inhibiting HIV
entry and replication of HIV-1 CCR5-variants [108]. KSHV
vMIP-II (ORFK4) inhibits the HIV-1 infection of T CDþ4 lym-
phocytes [109]. KSHV vMIP-III (ORFK4.1), on the other
hand, has an agonist property in CCR4 receptors, being a
chemotatractant for peripheral blood T lymphocytes
expressing TH2 cytokines [110], which manipulates the
balance between humoral and cytotoxic responses towards
the former. As a result, the immune response became non-
S. Ramos da Silva, D. Elgui de Oliveira / Cancer Letters 305 (2011) 175–185 181effective to eliminate KSHV-infected cells. Thus, KSHV
vMIPs seems to have an important role in KS pathogenesis,
and it is plausible to assume that the interference with the
availability of HIV-1 co-receptors might contribute to the
distinct biological features of classical and AIDS-KS.5. Mechanisms of viral cooperation in human
carcinogenesis: the PEL model
A unique scenario to evaluate the possible interplay be-
tween EBV and KSHV in carcinogenesis in the HIV setting is
PEL and PEL-based cell culture models. In dually infected
PEL cells, KSHV Rta and EBV Zta co-localize and interact
physically. The leucine heptapeptide repeat in KSHV Rta
and the leucine repeat region in EBV Zta are required for
this physical interaction. KSHV Rta is able to inhibit chem-
ically-induced EBV lytic gene expression, and EBV Zta
inhibits chemically-induced KSHV lytic expression like-
wise. EBV Zta and KSHV Rta also interact physically, and
it activates the EBV lytic gene expression, although this
process could be inhibited by KSHV Rta. As a matter of fact,
the initiation of the KSHV lytic cycle do correlates with a
decrease in the EBV lytic gene expression [111].
Latently EBV-infected cells that became infected with
KSHV show EBV lytic replication; likewise, latently KSHV-
infected cells that became infected with EBV reactivate
KSHV lytic replication. EBV/KSHV dually-infected cells
express EBV LMP-1, which negatively controls the KSHV ly-
tic replication, establishing a regulatory loop with KSHVFig. 2. Concept map produced with the CMapTools Software (Institute for Huma
in the present review regarding the putative mechanisms for HIV-1, EBV and KSH
The references for the studies indicating the experimental evidence for the indiRta. LMP-1 is expressed when EBV latently-infected cells
became infected with KSHV – as well as in KSHV la-
tently-infected cells infected with EBV – culminating in la-
tency for both gammaherpesviruses in the same cells
[112]. Worth to note, KSHV Rta binds to the EBV promoters
in vitro: in EBV/KSHV dually infected B-cells, the KSHV Rta
transactivates the EBV LMP-1 promoter and the C pro-
moter (Cp) through the cellular RBP-Jk transcription factor,
culminating in EBV latency type III in a latency I back-
ground. LMP-1 protein produced in latency III is responsi-
ble for the negative-feedback loop that resulted in the
expansion of PEL cells with no need of KSHV reactivation
or lysis of the infected-cells, and KSHV Rta contributes
indirectly in this effect [113].
It should be noted that viral latency is characterized by
the expression of few low-immunogenic viral proteins, so
that the immune response against the virus will be dimin-
ished. The maintenance of viral latency, therefore, favors
the immune escape and confers an increased risk for the
development of gammaherpesvirus-associated diseases.
On the other side, crucial EBV and KSHV oncoproteins are
latency-expressed products: KSHV LANA, for instance, is a
multifunctional protein that inhibits the transcriptional
activity of the p53 tumor suppressor protein, while EBV
LMP-1 constitutively activates the NF-jB signaling path-
way in EBV-infected B cells [114]. As it is well known, both
the impairment of p53 function and increased NF-jB acti-
vation culminate in increased cell proliferation and
survival in affected cells. Furthermore, in co-infected PEL
cells, the KSHV LANA N-terminal 340-aa tethers to a mSin3n and Machine Cognition, Ocala, FL, USA) summarizing the data evaluated
V cooperation in cell transformation and cancer development in humans.
cated assumption are provided. See text for details.
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moters (which drives the expression of most EBNA pro-
teins and EBNA1, respectively), while KSHV LANA
stimulates its own expression [115].
Therefore, it is plausible to consider that the mainte-
nance of viral latency due to EBV and KSHV crosstalk are
a key event in PEL pathogenesis.
6. Concluding remarks
The concept map [116] depicted in Fig. 2 summarizes
the current knowledge on putative mechanisms for EBV,
KSHV and HIV-1 cooperation in human carcinogenesis con-
solidated in the present review. As can be noted, critical
gears in these mechanisms are the HIV-1 LTR activation,
HIV-1 tat expression and the regulation of EBV and KSHV
biological cycles, with reﬂect in the expression of major
gammaherpesviral proteins with oncogenic potential.
Although disease models in which well-known viral
cooperation are sporadic (PEL, for instance), the available
evidence points out that possibly we are underestimating
the viral cooperation as an important event in the pathogen-
esis of virally-induced cancers. The same can be also said
about infection-associated cancers in general, aswemayex-
pect, at least, thatmore thanone infectious agentmayplay a
role an relevant element contributing for the alteredmicro-
environment that give rise to malignant cells. This is a very
excitingﬁeld for investigation, and it can be expected that in
the next years newdatawill provide us a better understand-
ing of the complex network in which infectious agents par-
ticipates in carcinogenesis, disclosing new and important
information on cancer biology itself.
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